REG - Greencare Capital - New investment
26 April 2021
Greencare Capital plc
("Greencare" or the "Company")
New investment
Greencare (AQUIS: GRE), the investment company focused on investing in medicinal cannabis and related areas, is pleased to announce that it has agreed to make an equity investment of £100,000 in Voyager Life Limited ("Voyager"), as part of a £741,000 fund raising by Voyager. This is the second new investment by Greencare in the past month.
Voyager, a health and wellness business focused on CBD and hemp seed oil, has developed a range of products under the Voyager and Voyager Life brands, including oils, gummies, bath and skincare products and is already generating revenues. It is currently developing a number of distribution channels which include direct sales, drop shipping, specialist retailers and online market places.
The CBD sector is expected to grow significantly in the short term, with the UK being the world's second largest market after the US. Voyager's management team have significant experience in the sector and to date, have made good progress in securing a novel foods licence which is now a requirement in order to be able to operate in this sector. Market regulation is therefore increasing, with the UK leading the way, and Voyager is very much focused on building a platform that is strictly regulatory compliant. This is particularly important in order to develop the right distribution channels for CBD products.
Voyager has already started the process of seeking its own stock market listing on the Aquis Stock Exchange Growth Market.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Enquiries:
Greencare Capital plc
Fabio Carretta
+39 345 23 59 968
Cairn Financial Advisers LLP
AQSE Corporate Adviser
Jo Turner / James Lewis
Walbrook PR Limited
Paul Vann/Nicholas Johnson
+44 20 7213 0885
+44 20 7933 8780
+44 7768 807631
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNEXUOUNRABUSUAR
